Merck

(IN BRIEF) Merck has partnered with NTU Singapore’s Digital Trust Centre (DTC) to advance digital trust technologies in industries requiring high security and compliance. The collaboration will deploy Merck’s digital-physical trust platform in Singapore, the first of its kind in … Read the full press release →

(IN BRIEF) Merck and Intel have launched a collaborative academic research initiative in Europe, bringing together eleven institutions from six countries. The program focuses on using Artificial Intelligence (AI) to make semiconductor manufacturing more sustainable, with research projects dedicated to … Read the full press release →

(IN BRIEF) Merck has officially opened a new €290 million biosafety testing facility in Rockville, Maryland, designed to meet the increasing global demand for biosafety testing services. This state-of-the-art facility consolidates various operations, including biosafety testing, analytical development, and cell … Read the full press release →

(IN BRIEF) TotalEnergies has signed a Power Purchase Agreement (PPA) with Saint-Gobain to supply renewable electricity to its facilities in France, starting in January 2026. This contract will provide 875 GWh of renewable energy over five years, sourced from TotalEnergies’ … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have previously undergone endocrine therapy. … Read the full press release →

(IN BRIEF) Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, modular production systems. Siemens will become Merck’s preferred global supplier, providing advanced hardware and software solutions via the Siemens Xcelerator platform. The … Read the full press release →

(IN BRIEF) Merck has signed an MoU with Gene Therapy Research Institution Co., Ltd. (GTRI) to support the production of gene therapy for Parkinson’s Disease using Merck’s Sf-RVN® Insect Cell Line platform. This collaboration aims to enhance the manufacturing process … Read the full press release →

(IN BRIEF) Merck has joined the “Semiconductor-X” research project, a consortium led by Intel Germany and the Fraunhofer IFF, focusing on the digitalization of semiconductor supply chains to improve resilience and sustainability. The project, funded by the German Federal Ministry … Read the full press release →

(IN BRIEF) Merck and The Michael J. Fox Foundation (MJFF) are collaborating to advance Parkinson’s disease research using Merck’s SMCxPRO® immunoassay technology. This initiative aims to detect biomarkers indicating cell dysfunction in PD patients, enhancing research into new treatment options … Read the full press release →

(IN BRIEF) Merck is investing €62 million in a new quality control facility at its Darmstadt headquarters as part of a larger €1.5 billion investment program. Scheduled for completion by mid-2025, the state-of-the-art facility will consolidate 135 employees into a … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, has inaugurated its expanded Life Science distribution center in Schnelldorf, Germany, following a €180 million investment that nearly doubled its size to 25,000 square meters. The upgraded facility now includes manual … Read the full press release →

(IN BRIEF) AstraZeneca is set to revolutionize cancer care with a slew of groundbreaking data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting. Over 100 abstracts will showcase 25 approved and potential new medicines, including two late-breaking … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated significant progress in treating HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. The high-level results from the DESTINY-Breast06 Phase … Read the full press release →

(IN BRIEF) AstraZeneca’s Truqap, in combination with Faslodex, has received a positive recommendation from the European Medicines Agency (EMA) for treating estrogen receptor-positive, HER2‑negative locally advanced or metastatic breast cancer with specific genetic alterations. The recommendation follows promising results from … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US FDA for treating adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received prior systemic … Read the full press release →

(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, announces a €14 million expansion of its M LabTM Collaboration Center in Shanghai, bolstering its support for the biopharmaceutical industry in China. The expansion includes new facilities such as a biology … Read the full press release →

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release →

(IN BRIEF) E. Merck KG, representing the Merck family’s interests in Merck KGaA, has disclosed the results of its regular board elections. Johannes Baillou, with 30 years of board experience at E. Merck KG, has been elected as Chairman of … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, has inaugurated the Merck Digital Hub in Singapore, its first digital hub outside of the US and Europe. Supported by the Singapore Economic Development Board (EDB), the hub aims to accelerate … Read the full press release →